Trial reportBMC neurology2026
Perimenstrual repetitive greater occipital nerve blockade for menstrual migraine: a randomized, double-blind, placebo-controlled trial.
Trial report in BMC neurology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07576309 (Perimenstrual Repetitive Greater Occipital Nerve Blockade for Menstrual Migraine), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Perimenstrual Repetitive Greater Occipital Nerve Blockade for Menstrual Migraine: A Randomized, Double-Blind, Placebo-Controlled Trial
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe main purpose of this study is to demonstrate the decrease in headache severity, pain duration and the number of painful days in a month after repetitive GON blockade applied with local anesthetic in menstrual migraine patients compared to the placebo group.
methodsThis randomized, double-blind, placebo-controlled study included 48 menstrual migraine patients. 24 patients received medication (0.5% bupivacaine) and 24 received placebo (saline) GON blockade twice a month for three months. Baseline data (month 0) relied on retrospective recall, whereas post-treatment data (months 3 and 6) were collected prospectively using a paper-based headache diary. The primary outcome was the change in headache severity (VAS score). Secondary outcomes included attack frequency, duration, number of headache days, analgesic use, and MIDAS scores.
resultsBaseline characteristics were similar between groups. At month 3, the active group showed a significantly greater reduction in the primary outcome, VAS scores, compared to the placebo group (decreasing from 8.75 ± 0.67 to 3.80 ± 3.18 vs. 8.71 ± 1.04 to 7.16 ± 1.31; p < 0.001). Significant reductions were also observed in secondary outcomes including monthly attack frequency (p = 0.002), mean attack duration (p < 0.001), number of headache days (p = 0.002), MIDAS scores (p = 0.003), and analgesic use (p = 0.009). Mild, transient injection-site tenderness was the only reported side effect. The clinical improvements were maintained at the 6th month, suggesting a potential sustained benefit, though natural history or late placebo responses cannot be fully excluded.
conclusionRepetitive perimenstrual GON blockade may be an effective short-term prophylaxis for MM. However, the observed effects on the subjective primary endpoint (VAS) may be partially attributable to imperfect blinding, and all secondary outcomes are exploratory. Further studies are needed to confirm these findings and exclude natural history or placebo responses.
trial registrationClinicalTrials.gov, NCT07576309. Registered on 08 May 2026. Retrospectively registered.
Indexed as
Identifiers
42920151What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.